ArticleFrontiers in oncology2026
Penile pseudomyogenic hemangioendothelioma/epithelioid sarcoma-like hemangioendothelioma: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomyogenic hemangioendothelioma (PHE) is a rare vascular neoplasm predominantly affecting young adult males, often presenting in soft tissues of the extremities, with exceptionally rare cases in the penile region. This report details the case of a 45-year-old Han Chinese male with a painful penile nodule misdiagnosed as Peyronie's disease due to its clinical presentation. Initial evaluations, including ultrasound and laboratory tests, suggested uncertainty regarding the lesion's nature. Surgical excision was performed, revealing a dark purplish-red mass embedded in the tunica albuginea. Histopathological analysis supported a diagnosis of PHE, highlighted by immunohistochemical markers including strong positivity for FOSB and CD31. The postoperative course demonstrated good recovery and resolution of symptoms with no recurrence observed during follow-up. This case emphasizes the diagnostic challenge posed by PHE due to its deceptive clinical features and the necessity for histopathological examination coupled with immunophenotypic profiling for accurate diagnosis. Increased awareness of PHE is crucial for urologists and andrologists to improve diagnostic accuracy and facilitate timely management of this rare entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.